Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. We have a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. 

Global Genomic Biomarkers Market to reach USD 9.8 billion by 2027

Global Genomic Biomarkers Market Size study, by Application (Oncology, Cardiovascular diseases, Neurological diseases, Others), by End-User (Diagnostic and research laboratories, Hospitals, Others) and Regional Forecasts 2020-2027

Product Code: HALB_54013426
Publish Date: 25-01-2021
Page: 200

Global Genomic Biomarkers Market is valued approximately at USD 3.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 12.7% over the forecast period 2020-2027. Genomic biomarkers possess the attribute of Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) that are typically used as a disease indicator, disease classification, and therapy assortment. They are minimally or non-invasive tools generally applied in imaging technology to deliver clear imaging of cancerous tumors & other complications, as well as reduce the possibilities of radiation treatment throughout CT scans and MRI scans. These biomarkers are further utilized to assess hyperkalemia, high blood pressure, and other monogenic circumstances. They reveal the function of gene, manifestation of a gene, and supervision of a gene in typical biologic procedures, pathogenic procedures, and responses to therapeutics. The increase in the genomic biomarker market is significantly imputed to the fact that the technological advancements in genomic biomarker, such as Gene Expression Profiling (microarray) and Next-Generation Sequencing (NGS, is relentlessly expanding across the globe. Moreover, the rise in prevalence of chronic diseases such as cancer and cardiac disorder aligned with rising availability of funding for genomic biomarker research are the few other factors responsible for the CAGR of the market during the forecast period. According to the American Heart Association, CVD is the leading cause of death around the world. There were about 17.6 million deaths due to CVD registered in 2016, which is likely to grow almost 23.6 million by 2030. While there were around 17 million new cases of cancer and 9.5 million deaths were totaled in 2018 and is expecting to grow over 27.5 million new cancer cases and 16.3 million deaths by the year 2040. This, in turn, is expected to strengthen the market growth all over the world. However, the stringent government regulation coupled with the lack of standardization for validating the biomarker are the few factors restraining the market growth over the forecast period of 2020-2027.

The regional analysis of the global Genomic Biomarkers market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the supportive government policies and funding for genomic biomarker research along with the presence of a significant number of market vendors in the region. Whereas North America is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of cancer and cardiology diseases along with the presence of significant pharmaceutical and biotechnological infrastructure in the United States and Canada would create lucrative growth prospects for the Genomic Biomarkers market across the Asia-Pacific region.

Major market player included in this report are:
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Aepodia SA
Myriad Genetics Inc.
Eurofins Scientific
Bio-Rad Laboratories Inc.
Almac Group
Aros Applied Biotechnology A/S
Epigenomics AG

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application:
Cardiovascular diseases
Neurological diseases

By End-User:
Diagnostic and research laboratories

By Region:
North America

Asia Pacific
South Korea
Latin America
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Genomic Biomarkers Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. Genomic Biomarkers Market, by Region, 2018-2027 (USD Billion)
1.2.2. Genomic Biomarkers Market, by Application, 2018-2027 (USD Billion)
1.2.3. Genomic Biomarkers Market, by End-User, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Genomic Biomarkers Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Genomic Biomarkers Market Dynamics
3.1. Genomic Biomarkers Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Genomic Biomarkers Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Genomic Biomarkers Market, by Application
5.1. Market Snapshot
5.2. Global Genomic Biomarkers Market by Application, Performance – Potential Analysis
5.3. Global Genomic Biomarkers Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
5.4. Genomic Biomarkers Market, Sub Segment Analysis
5.4.1. Oncology
5.4.2. Cardiovascular diseases
5.4.3. Neurological diseases
5.4.4. Others
Chapter 6. Global Genomic Biomarkers Market, by End-User
6.1. Market Snapshot
6.2. Global Genomic Biomarkers Market by End-User – Potential Analysis
6.3. Global Genomic Biomarkers Market Estimates & Forecasts by End-User 2017-2027 (USD Billion)
6.4. Genomic Biomarkers Market, Sub Segment Analysis
6.4.1. Diagnostic and research laboratories
6.4.2. Hospitals
6.4.3. Others
Chapter 7. Global Genomic Biomarkers Market, Regional Analysis
7.1. Genomic Biomarkers Market, Regional Market Snapshot
7.2. North America Genomic Biomarkers Market
7.2.1. U.S. Genomic Biomarkers Market Application breakdown estimates & forecasts, 2017-2027 End-User breakdown estimates & forecasts, 2017-2027
7.2.2. Canada Genomic Biomarkers Market
7.3. Europe Genomic Biomarkers Market Snapshot
7.3.1. U.K. Genomic Biomarkers Market
7.3.2. Germany Genomic Biomarkers Market
7.3.3. France Genomic Biomarkers Market
7.3.4. Spain Genomic Biomarkers Market
7.3.5. Italy Genomic Biomarkers Market
7.3.6. Rest of Europe Genomic Biomarkers Market
7.4. Asia-Pacific Genomic Biomarkers Market Snapshot
7.4.1. China Genomic Biomarkers Market
7.4.2. India Genomic Biomarkers Market
7.4.3. Japan Genomic Biomarkers Market
7.4.4. Australia Genomic Biomarkers Market
7.4.5. South Korea Genomic Biomarkers Market
7.4.6. Rest of Asia Pacific Genomic Biomarkers Market
7.5. Latin America Genomic Biomarkers Market Snapshot
7.5.1. Brazil Genomic Biomarkers Market
7.5.2. Mexico Genomic Biomarkers Market
7.6. Rest of The World Genomic Biomarkers Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Thermo Fisher Scientific Inc. Key Information Overview Financial (Subject to Data Availability) Product Summary Recent Developments
8.2.2. F. Hoffmann-La Roche Ltd.
8.2.3. Aepodia SA
8.2.4. Myriad Genetics Inc.
8.2.5. Eurofins Scientific
8.2.6. Qiagen
8.2.7. Bio-Rad Laboratories Inc.
8.2.8. Almac Group
8.2.9. Aros Applied Biotechnology A/S
8.2.10. EpiGenomic AG
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

The study of the market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. Our analysts contact company executives, managers, key opinion leaders, and industry experts. This enables our analyst to derive the closest possible figures without any major deviations in the actual number.

Primary Research Sources:

  • Interview conducted with raw material suppliers & manufacturers.
  • Interview conducted with manufacturers, suppliers & distributors, researchers, & representatives of regulatory bodies.
  • Interview conducted with market players, industry experts, & independent consultants.
  • Secondary Research Sources:
  • Purchased Database: D&B Hoovers, Bloomberg, Inc., Business Information Industry Association, NAICS Association.
  • Internal Database: White papers, Certified Publications, Articles by Recognized Authors and Regulatory Bodies.
  • Government Databases: Food and Agriculture Organization (FAO), European Industrial Hemp Association (EIHA), World Health Organization (WHO), Food and Drug Administration (FDA), International Telecommunication Union (ITU), United States Department of Agriculture (USDA), International organization of Motor Vehicle Manufacturers (OICA).

Need Assistance

Contact Person -
Krishant Mennon
Call us @
+ 91 99931 15879
Email: sales@bizwitresearch.com


Why Choose Us?

Quality over Quantity

Backed by 60+ paid data sources our reports deliver crisp insights with no compromise quality.

Analyst Support

24x7 Chat Support plus
free analyst hours with every purchase

Flawless Methodology

Our 360-degree approach of market study, our research methods leave stones unturned.

Enquiry Now